Donor-derived cell-free DNA predicted allograft rejection and severe microvascular inflammation in kidney transplant recipients
10.3389/fimmu.2024.1433918 · doi-reference
HLA type and the effect of HLA antibodies in kidney, liver, and pancreas transplantation: A review
10.18502/ajmb.v18i1.21042 · doi-reference
Treg therapy for the induction of immune tolerance in transplantation—not lost in translation
10.3390/ijms24021752 · doi-reference
Can regulatory T cells improve outcomes of sensitised patients after HLA-Ab incompatible renal transplantation: study protocol for the Phase IIa GAMECHANgER-1 trial
10.1186/s12882-023-03157-7 · doi-reference
Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial
10.1136/bmj.m3734 · doi-reference
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials
10.1016/s0140-6736(20)30167-7 · doi-reference
Regulatory T cells in solid organ transplantation
10.1002/cti2.1099 · doi-reference
Chimeric HLA antibody receptor T cell therapy for humoral transplant rejection
10.1093/ndt/gfae160 · doi-reference
Chimeric antigen receptor (CAR) regulatory T-cells in solid organ transplantation
10.3389/fimmu.2022.874157 · doi-reference
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
10.1182/blood.2024025454 · doi-reference
Rejection-focused precision medicine in kidney transplantation: Biology, biomarkers, and artificial intelligence
10.3390/life16040674 · doi-reference
Genetic variants of the HLA-G/LILRB1 ligand-receptor axis in donors or recipients are prognostic covariates for rejection after living kidney transplantation
10.3389/fimmu.2025.1697839 · doi-reference
Biological characteristics of HLA-G and its role in solid organ transplantation
10.3389/fimmu.2022.902093 · doi-reference
Biopsy-based transcriptomics in the diagnosis of kidney transplant rejection
10.1097/mnh.0000000000000974 · doi-reference
Single-cell spatial transcriptomics reveal intraglomerular cell activation and ligand-receptor relationships in chronic, active antibody mediated rejection
10.1016/j.kint.2025.08.042 · doi-reference
Systematic biopsy-based transcriptomics and diagnosis of antibody-mediated kidney transplant rejection in clinical practice
10.2215/cjn.0000000000000490 · doi-reference
Critical roles of mTOR complex 1 and 2 for T follicular helper cell differentiation and germinal center responses
10.7554/elife.17936 · doi-reference
Long-term outcomes after conversion to a belatacept-based immunosuppression in kidney transplant recipients
10.2215/cjn.0000000000000411 · doi-reference
Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: Final results from BENEFIT-EXT, a phase III randomized study
10.1111/ajt.13830 · doi-reference
De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies
10.1111/ajt.14721 · doi-reference
Combined immunotherapy with belatacept and BTLA overexpression attenuates acute rejection following kidney transplantation
10.3389/fimmu.2021.618737 · doi-reference
T follicular helper cells as a new target for immunosuppressive therapies
10.3389/fimmu.2017.01510 · doi-reference
Impact of intra-patient variability of tacrolimus on allograft function and CD4 + /CD8 + ratio in kidney transplant recipients: a retrospective single-center study
10.1007/s11096-024-01726-w · doi-reference
Long-term immunosuppression management
10.2215/cjn.15040920 · doi-reference
Carfilzomib-based antibody mediated rejection therapy in pediatric kidney transplant recipients
10.1111/petr.14534 · doi-reference
A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection
10.1681/asn.2017070818 · doi-reference
The preliminary results of bortezomib used as a primary treatment for an early acute antibody-mediated rejection after kidney transplantation—a single-center case series
10.3390/jcm9020529 · doi-reference
Bortezomib alleviates antibody‐mediated rejection in kidney transplantation by facilitating Atg5 expression
10.1111/jcmm.16998 · doi-reference
Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)
10.1186/s13063-024-08020-0 · doi-reference
Tocilizumab-based treatment of microvascular inflammation in kidney transplant recipients: A retrospective study
10.3389/ti.2025.14502 · doi-reference
Tocilizumab and active antibody-mediated rejection in kidney transplantation: A literature review
10.3389/fimmu.2022.839380 · doi-reference
Anti-interleukin-6 antibody clazakizumab in antibody-mediated renal allograft rejection: Accumulation of antibody-neutralized interleukin-6 without signs of proinflammatory rebound phenomena
10.1097/tp.0000000000004285 · doi-reference
Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: Results of a randomized double-blind placebo-controlled pilot study
10.1111/ajt.13871 · doi-reference
High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine
10.15585/mmwr.mm6627e1 · doi-reference
Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts
10.1097/tp.0000000000000184 · doi-reference
Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: A pilot randomized controlled trial
10.1111/ajt.14001 · doi-reference
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients
10.1111/j.1600-6143.2011.03757.x · doi-reference
The multifaceted role of complement in kidney transplantation
10.1038/s41581-018-0071-x · doi-reference
Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study
10.1186/s12882-025-03951-5 · doi-reference
CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection
10.1097/tp.0000000000003247 · doi-reference
